{"id":840269,"date":"2025-04-22T16:40:20","date_gmt":"2025-04-22T20:40:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/"},"modified":"2025-04-22T16:40:20","modified_gmt":"2025-04-22T20:40:20","slug":"kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/","title":{"rendered":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <span class=\"xn-person\">Kuehn Law<\/span>, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of <b><u>Sage Therapeutics, Inc. (NASDAQ: SAGE)<\/u><\/b>\u00a0breached their fiduciary duties to shareholders.\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg\" title=\"Kuehn Law, PLLC (PRNewsfoto\/Kuehn Law, PLLC)\" alt=\"Kuehn Law, PLLC (PRNewsfoto\/Kuehn Law, PLLC)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone&#8217;s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the company had led investors to believe; (iv) accordingly, SAGE-718&#8217;s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than the company had led investors to believe; (vi) accordingly, SAGE-324&#8217;s clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the company&#8217;s public statements were materially false and misleading at all relevant times.<\/p>\n<p>If you currently own SAGE <b>and purchased prior to <span class=\"xn-chron\">April 12, 2021<\/span><\/b>please\u00a0contact\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4410531-1&amp;h=3538658055&amp;u=https%3A%2F%2Fget-in-touch-85e72c.zapier.app%2Fcontact-kuehn-law&amp;a=Justin+Kuehn%2C+Esq.%C2%A0here\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Justin Kuehn, Esq.<\/span>\u00a0here<\/a>,\u00a0by email at\u00a0<a href=\"mailto:justin@kuehn.law\" target=\"_blank\" rel=\"nofollow\">justin@kuehn.law<\/a> or call (833) 672-0814. <b>The consultation and case are free with no obligation to you. <span class=\"xn-person\">Kuehn Law<\/span> pays all case costs and does not charge its investor clients.<\/b><i>Shareholders should contact the firm immediately as there may be limited time to enforce your rights.<\/i>\u00a0<\/p>\n<p>\n        <b>Why Your Participation Matters:<\/b>\n      <\/p>\n<p>As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets.\u00a0<i>Your investment. Your voice. Your future.<\/i><sup>\u2122<\/sup>\u00a0<\/p>\n<p>For additional information, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4410531-1&amp;h=2771105577&amp;u=https%3A%2F%2Fwww.kuehn.law%2Fservices%2Fshareholder-derivative-litigation&amp;a=Shareholder+Derivative+Litigation+-+Kuehn+Law\" target=\"_blank\" rel=\"nofollow\">Shareholder Derivative Litigation &#8211; <span class=\"xn-person\">Kuehn Law<\/span><\/a>.<\/p>\n<p>Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>Contacts:<br \/><span class=\"xn-person\">Kuehn Law<\/span>, PLLC<br \/><span class=\"xn-person\">Justin Kuehn, Esq.<\/span><br \/>53 Hill Street, Suite 605<br \/><span class=\"xn-location\">Southampton, NY<\/span> 11968<br \/><a href=\"mailto:justin@kuehn.law\" target=\"_blank\" rel=\"nofollow\">justin@kuehn.law<\/a><br \/>(833) 672-0814<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY70110&amp;sd=2025-04-22\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-302434949.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-302434949.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Kuehn Law<\/span>, PLLC<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY70110&amp;Transmission_Id=202504221616PR_NEWS_USPR_____NY70110&amp;DateId=20250422\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , April 22, 2025 \/PRNewswire\/ &#8212; Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE)\u00a0breached their fiduciary duties to shareholders.\u00a0 According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone&#8217;s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-840269","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , April 22, 2025 \/PRNewswire\/ &#8212; Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE)\u00a0breached their fiduciary duties to shareholders.\u00a0 According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone&#8217;s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the &hellip; Continue reading &quot;Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T20:40:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm\",\"datePublished\":\"2025-04-22T20:40:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/\"},\"wordCount\":358,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2309909\\\/Kuehn_Law_PLLC.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/\",\"name\":\"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2309909\\\/Kuehn_Law_PLLC.jpg\",\"datePublished\":\"2025-04-22T20:40:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2309909\\\/Kuehn_Law_PLLC.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2309909\\\/Kuehn_Law_PLLC.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/","og_locale":"en_US","og_type":"article","og_title":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","og_description":"PR Newswire NEW YORK , April 22, 2025 \/PRNewswire\/ &#8212; Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE)\u00a0breached their fiduciary duties to shareholders.\u00a0 According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone&#8217;s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the &hellip; Continue reading \"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-22T20:40:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm","datePublished":"2025-04-22T20:40:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/"},"wordCount":358,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/","name":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg","datePublished":"2025-04-22T20:40:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2309909\/Kuehn_Law_PLLC.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-sage-therapeutics-inc-to-contact-law-firm-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=840269"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/840269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=840269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=840269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=840269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}